Longitudinal Tumor Microenvironment Analysis in Extensive Stage SCLC Patients Treated with Dual Checkpoint Inhibitor Blockade

被引：0
|
作者：
Chiang, A. [1 ]
Matera, R. [1 ]
Ashley, K. [2 ]
Rajendran, B. K. [2 ]
Schalper, K. A. [2 ]
机构：
[1] Yale Univ, Sch Med, New Haven, CT USA
[2] Yale Univ, New Haven, CT USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
SCLC; Tumor Microenvironment; immunotherapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.13D.07
引用
收藏
页码：S362 / S362
页数：1
相关论文
共 42 条
  • [41] Prospective evaluation of immunological, molecular-genetic, image-based and microbial analyses to characterize tumor response and control in patients with unresectable stage III NSCLC treated with concurrent chemoradiotherapy followed by consolidation therapy with durvalumab (PRECISION): protocol for a prospective longitudinal biomarker study
    Kaesmann, Lukas
    Taugner, Julian
    Eze, Chukwuka
    Nieto, Alexander
    Pelikan, Carolyn
    Floersch, Benedikt
    Kenndoff, Saskia
    Hofer, Thomas P.
    Noessner, Elfriede
    Schulz, Christian
    Unterrainer, Marcus
    Tufman, Amanda
    Klauschen, Frederick
    Jung, Andreas
    Neumann, Jens
    Kumbrink, Jorg
    Reinmuth, Niels
    Bartenstein, Peter
    Belka, Claus
    Manapov, Farkhad
    TRANSLATIONAL LUNG CANCER RESEARCH, 2022, 11 (07) : 1503 - 1509
  • [42] Efficacy and safety of anti-PD-1/PD-L1-based dual immunotherapies versus PD-1/PD-L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta-analysis
    Chen, Yueying
    Han, Hedong
    Cheng, Jing
    Cheng, Qinpei
    Zhu, Suhua
    Zhan, Ping
    Liu, Hongbing
    Song, Yong
    Lv, Tangfeng
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 73 (08)
12345